Skip to content
Assyro AI
FDA Purple Book product · 351(a) biologic

Tysabri

natalizumab

Tysabri, BLA 125104, is listed in the FDA Purple Book as a 351(a) reference biologic. This page consolidates 1 exact FDA presentation row, and 1 FDA rows name-link 351(k) follow-on products to its reference family. It separates the BLA applicant from any unverified manufacturer and does not infer clinical labeling, pharmacy substitution, commercial availability, or patent conclusions.

351(a)BLA 125104RxLicensed Biogen Inc.
Approved
Nov 23, 2004
License type
351(a)
Marketing
Rx
Listed patents
32
Tysabri (natalizumab) is Biogen Inc.'s FDA-licensed 351(a) biologic under BLA 125104, approved in 2004. The FDA Purple Book lists 32 published patents for it, the last expiring 2036. 1 distinct approved follow-on biologic explicitly reference Tysabri (Tyruko), making its reference-product role visible in the loaded family data.

Sourced from the FDA Purple Book · verified Oct 08, 2026

What this Purple Book record establishes

Regulatory interpretation
Ask AI

BLA number

125104

Regulatory role

351(a) reference biologic

Applicant

Biogen Inc.

Applicant is not automatically the physical manufacturer.

Presentations

1

Exact FDA presentation rows under this BLA.

Approval

Nov 23, 2004

Follow-on biologics

1

Tysabri is a 351(a) reference biologic supported by exact-BLA evidence.

1 distinct licensed follow-on biologic in the loaded Purple Book data name Tysabri as their reference product; exact-BLA patent or exclusivity fields, or an unambiguous single-BLA name match, support this page's role.

Substitution boundary

Substitution status belongs to an individual follow-on product; it cannot be inferred from the reference product alone.

Key dates

Licensure & exclusivity
Ask AI
  1. Approval

    Approval date of this BLA submission.

    Nov 23, 2004

    22 yr 4 mo ago

  2. Today

Pharmaceutical detail

FDA product record
Ask AI

Strength

300MG/15ML (20MG/ML)

Dosage form

Injection

Route

Intravenous

Presentation

Single-Dose Vial

Center

CDER

License number

1697

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Exact presentation matrix

One row per FDA presentation under this exact BLA. Missing cells remain unavailable rather than being borrowed from another product.

Exact FDA Purple Book presentation rows for this BLA
ProductStrengthDosage formRoutePresentationLicensureMarketing
001300MG/15ML (20MG/ML)InjectionIntravenousSingle-Dose VialLicensedRx

Exact-source evidence coverage

Labeling & approval review

Current product label

Candidate awaiting exact-BLA match

FDA exposes a label link on this Purple Book row, but labeling content remains unavailable until the document is independently matched to this exact BLA and its presentations.

Inspect FDA label candidate

FDA approval evidence

Not applicable to 351(a)

A biosimilar totality-of-evidence summary is not applicable to this 351(a) record. Product-specific clinical content still requires an exact-BLA label or review source.

Human review pending

Automated BLA-level interpretation has not been marked human-reviewed. The research queue contains 1 exact-source task. Labeling and approval-review claims stay unavailable until their own match gate passes.

Reference product family

Biosimilars & interchangeables

1 distinct 351(k) follow-on biologic are linked through FDA-stated reference names to Tysabri; 0 are designated interchangeable and 1 has a licensed status in the loaded snapshot.

Exact-BLA patent, exclusivity, or unambiguous linked-family evidence supports this page's reference role. Name-linked licensed biosimilars and interchangeables are listed below.

Reference-family comparison

Purple Book comparison of products in this reference family
ProductDesignationBLAApprovedPresentationMarketing
Tysabrinatalizumab351(a) reference biologic125104Nov 23, 2004300MG/15ML (20MG/ML) · IntravenousRx
Tyrukonatalizumab-sztn351(k) biosimilar761322Aug 24, 2023300MG/15ML (20MG/ML) · IntravenousRx

Published patents

BPCIA patent list
Ask AI
Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
PatentExpiresInSource
7,157,276Jun 21, 20242 yr 5 mo agoFDA
7,759,117Jun 21, 20242 yr 5 mo agoFDA
10,705,095Apr 04, 20268 mo agoFDA
9,709,575Apr 04, 20268 mo agoFDA
8,871,449Apr 12, 20267 mo agoFDA
10,233,245Feb 28, 2027in 3 moFDA
11,292,845Feb 28, 2027in 3 moFDA
9,493,567Mar 05, 2027in 3 moFDA
8,124,350Aug 02, 2027in 8 moFDA
9,696,307Feb 05, 2030in 3 yr 3 moFDA
9,005,926Oct 01, 2030in 3 yr 11 moFDA
9,212,379Nov 28, 2030in 4 yr 1 moFDA
9,096,879Jan 07, 2031in 4 yr 2 moFDA
10,444,234Jan 11, 2031in 4 yr 2 moFDA
11,287,423Jan 11, 2031in 4 yr 2 moFDA
8,318,416Jan 20, 2031in 4 yr 3 moFDA
10,308,706Feb 05, 2031in 4 yr 3 moFDA
8,809,049May 22, 2031in 4 yr 7 moFDA
9,109,015Aug 13, 2031in 4 yr 10 moFDA
9,316,641Jan 09, 2032in 5 yr 2 moFDA
10,590,454May 11, 2032in 5 yr 7 moFDA
9,790,533May 11, 2032in 5 yr 7 moFDA
9,562,252May 11, 2033in 6 yr 7 moFDA
10,119,976May 27, 2034in 7 yr 7 moFDA
10,677,803May 27, 2034in 7 yr 7 moFDA
11,280,794May 27, 2034in 7 yr 7 moFDA
10,676,772Aug 19, 2034in 7 yr 10 moFDA
9,994,968Aug 19, 2034in 7 yr 10 moFDA
10,023,831Mar 17, 2035in 8 yr 5 moFDA
11,124,760Aug 27, 2035in 8 yr 11 moFDA
11,268,119Feb 21, 2036in 9 yr 5 moFDA
10,844,416Jun 01, 2036in 9 yr 8 moFDA

Practical characteristics and limits

Source-bounded interpretation

Presentation coverage

1 exact FDA presentation row is consolidated under this BLA rather than split across duplicate pages.

Administration fields

The loaded rows list Intravenous and Injection; these are regulatory presentation fields, not dosing instructions.

Applicant boundary

Biogen Inc. is the listed BLA applicant. The page does not relabel the applicant as manufacturer, labeler, distributor, or commercial supplier without an exact product-specific source.

Regulatory comparison

Tysabri is a 351(a) reference biologic supported by exact-BLA evidence. Family comparisons preserve each BLA's own designation and do not use Orange Book therapeutic-equivalence terminology.

Source provenance

FDA Purple Book data
Source kind · Monthly download
Checked Oct 08, 2026
FDA release · September 2026
  • advanced-searchAdvanced Search · Oct 08, 2026
  • monthly-downloadMonthly download · Oct 08, 2026
  • monthly-downloadMonthly download · Sep 21, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

What this record does not establish

  • Purple Book marketing status is a regulatory field, not real-time commercial inventory or launch status.
  • The listed applicant or BLA holder is not automatically the product’s physical manufacturer, labeler, or distributor.
  • Biosimilar status and interchangeability are distinct FDA designations; neither is a therapeutic-equivalence code from the Orange Book.
  • A missing patent or exclusivity row is not proof that no relevant rights exist, and listed patent information is not a freedom-to-operate opinion.
  • Approved uses, dosing, warnings, and clinical evidence require the exact current product label or approval package and are not inferred from the reference product.

Change history

Record versions
  • v8Oct 08, 2026
  • v7Oct 08, 2026
  • v6Sep 21, 2026
  • v5Aug 11, 2026
  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Tysabri: frequently asked questions

Licensure, biosimilar status, exclusivity, and patents for this biologic, from the FDA Purple Book.

Built directly from the FDA Purple Book database of licensed biological products. License types, approval and exclusivity dates, and the patent list match the official FDA record. The Purple Book patent list reflects the statutory BPCIA patent exchange and is not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Tysabri

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo